A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.
about
A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
A phase I/II trial of AT9283, ...... ls for children with leukemia.
@en
type
label
A phase I/II trial of AT9283, ...... ls for children with leukemia.
@en
prefLabel
A phase I/II trial of AT9283, ...... ls for children with leukemia.
@en
P2093
P2860
P50
P356
P1476
A phase I/II trial of AT9283, ...... als for children with leukemia
@en
P2093
D Hargrave
D Lancaster
K E Swales
P2860
P356
10.1002/PBC.26351
P577
2016-12-01T00:00:00Z